Birchview Capital, LP Ventyx Biosciences, Inc. Transaction History
Birchview Capital, LP
- $95 Million
- Q2 2025
A detailed history of Birchview Capital, LP transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Birchview Capital, LP holds 28,800 shares of VTYX stock, worth $101,664. This represents 0.06% of its overall portfolio holdings.
Number of Shares
28,800
Previous 28,800
-0.0%
Holding current value
$101,664
Previous $33,000
84.85%
% of portfolio
0.06%
Previous 0.03%
Shares
8 transactions
Others Institutions Holding VTYX
# of Institutions
122Shares Held
49.4MCall Options Held
70.4KPut Options Held
51.4K-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct5.9MShares$20.8 Million0.03% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$16.8 Million0.0% of portfolio
-
Affinity Asset Advisors, LLC New York, NY4.54MShares$16 Million1.63% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.16MShares$11.2 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA3.1MShares$10.9 Million0.4% of portfolio
About Ventyx Biosciences, Inc.
- Ticker VTYX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,527,200
- Market Cap $200M
- Description
- Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...